DAIICHI-SANKYO-DS3939-077
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2, Open-Label, Multicenter, First-in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors
ECOG-EA7222
Phase III
OPEN TO ACCRUAL
A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
LOXO-J5M-OX-JOXA
Phase I
OPEN TO ACCRUAL
An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
VOLASTRA-VLS-1488-2201
Phase I/II
OPEN TO ACCRUAL
A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects with Advanced Cancer